Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Research ArticleOriginal Article

Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers

Huahui Yu, Jieyu Li, Yuan Yuan, Yu Chen, Jingwen Hong, Chunmei Ye, Wansong Lin, Huijing Chen, Zengqing Guo, Bo Li and Yunbin Ye
Cancer Biology & Medicine November 2021, 18 (4) 1053-1065; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0022
Huahui Yu
1The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jieyu Li
2Laboratory of Immuno-Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou 350014, China
3Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuan Yuan
4BGI-Shenzhen, Shenzhen 518083, China
5BGI Education Center, University of Chinese Academy of Sciences, Shenzhen 518083, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Chen
3Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, China
6Department of Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou 350014, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingwen Hong
1The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chunmei Ye
1The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wansong Lin
2Laboratory of Immuno-Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou 350014, China
3Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huijing Chen
2Laboratory of Immuno-Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou 350014, China
3Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zengqing Guo
3Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, China
6Department of Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou 350014, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Li
4BGI-Shenzhen, Shenzhen 518083, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yunbin Ye
1The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China
2Laboratory of Immuno-Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou 350014, China
3Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yunbin Ye
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Supplementary Materials
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Flow chart of this study.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Affinity and stability detection of neoepitopes. (A) Affinity between different neoepitopes and HLA-A0201 molecules. Flow cytometry data are representative of 3 independent experiments. (B) Stability of different neoepitopes and HLA-0201 molecules after forming pMHC complexes. The dissociation rate was calculated as follows: dissociation rate = [mean PE fluorescence with given peptide (t = 0, 6, 12, 18, 24 h) – mean PE fluorescence without peptide (t = 0, 6, 12, 18, 24 h)]/[mean PE fluorescence with a given peptide (t = 0 h) – mean PE fluorescence without peptide (t = 0 h)]. Data represent the mean ± SD of 3 independent experiments.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    The effect of different neoepitopes on T cells (A) IFN-γ secretion in T cells stimulated by dendritic cells (DCs) with different neoepitopes. Data represent the mean ± SD of 3 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. (B) Proliferation of T cells stimulated by DCs with different neoepitopes. Flow cytometry data are representative of 3 independent experiments.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    The cytotoxicity of neoepitope-specific cytotoxic T cells (CTLs) stimulated by wild-type and altered neoepitopes on target cells. (A) Comparison of the cytotoxicity of mutABCA2-specific CTLs and mutABCA2L2-specific CTLs on T2 cells loaded with mutABCA2. Data represent the mean ± SD of 3 independent experiments. (B) Comparison of the cytotoxicity of mutSP140-specific CTLs and mutSP140Y1-specific CTLs on T2 cells loaded with mutSP140. Data represent the mean ± SD of 3 independent experiments. (C) Comparison of the cytotoxicity of mutSTOM-specific CTLs and mutSTOML2-specific CTLs on T2 cells loaded with mutSTOM. Data represent the mean ± SD of 3 independent experiments.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5

    Recognition and activation of neoepitope-specific cytotoxic T cells (CTLs) stimulated by wild-type neoepitopes and altered neoepitopes on T2 cells loaded with neoepitopes. (A) IFN-γ expression in wild-type neoepitope-specific CTLs and altered neoepitope-specific CTLs. Data represent the mean ± SD of 3 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. (B) TNF-α expression in wild-type neoepitope-specific CTLs and altered neoepitope-specific CTLs. Data represent the mean ± SD of 3 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. (C) Perforin expression in wild-type neoepitope-specific CTLs and altered neoepitope-specific CTLs. The flow cytometry data are representative of 3 independent experiments. Data represent the mean ± SD of 3 independent experiments.

Tables

  • Figures
  • Supplementary Materials
    • View popup
    Table 1

    Affinity prediction and detection results of wild-type neoepitopes and altered neoepitopes

    Position of peptideSequencesPrediction algorithms-IEDBFIaDC50b
    mutABCA2FIGITATVV3.73.32 ± 0.36<18 h
    mutABCA2L2FLGITATVV1.04.49 ± 0.42>18 h
    mutSP140PLLPVTCGV2.13.79 ± 0.50>24 h
    mutSP140Y1YLLPVTCGV0.25.20 ± 0.57>24 h
    mutSTOMSVIISVDGV4.64.27 ± 0.52<18 h
    mutSTOML2SLIISVDGV1.04.71 ± 0.41>18 h
    HIV-1 peptideILKEPVHGV1.84.76 ± 0.41>24 h

    aFI = (average PE fluorescence with the given peptide – average PE fluorescence without peptide)/(average PE fluorescence without peptide). bDC50 is defined as the time required for 50% dissociation of the pMHC complex stabilized at t = 0 h.

    Supplementary Materials

    • Figures
    • Tables
    • [cbm-18-1053-s001.pdf]
    PreviousNext
    Back to top

    In this issue

    Cancer Biology & Medicine: 18 (4)
    Cancer Biology & Medicine
    Vol. 18, Issue 4
    1 Nov 2021
    • Table of Contents
    • Index by author
    Print
    Download PDF
    Email Article

    Thank you for your interest in spreading the word on Cancer Biology & Medicine.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers
    (Your Name) has sent you a message from Cancer Biology & Medicine
    (Your Name) thought you would like to see the Cancer Biology & Medicine web site.
    Citation Tools
    Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers
    Huahui Yu, Jieyu Li, Yuan Yuan, Yu Chen, Jingwen Hong, Chunmei Ye, Wansong Lin, Huijing Chen, Zengqing Guo, Bo Li, Yunbin Ye
    Cancer Biology & Medicine Nov 2021, 18 (4) 1053-1065; DOI: 10.20892/j.issn.2095-3941.2021.0022

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers
    Huahui Yu, Jieyu Li, Yuan Yuan, Yu Chen, Jingwen Hong, Chunmei Ye, Wansong Lin, Huijing Chen, Zengqing Guo, Bo Li, Yunbin Ye
    Cancer Biology & Medicine Nov 2021, 18 (4) 1053-1065; DOI: 10.20892/j.issn.2095-3941.2021.0022
    Digg logo Reddit logo Twitter logo Facebook logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • Introduction
      • Materials and methods
      • Results
      • Discussion
      • Conclusions
      • Supporting Information
      • Grant support
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • References
    • PDF

    Related Articles

    • No related articles found.
    • Google Scholar

    Cited By...

    • No citing articles found.
    • Google Scholar

    More in this TOC Section

    • Acetylated-PPARγ expression is regulated by different P53 genotypes associated with the adipogenic differentiation of polyploid giant cancer cells with daughter cells
    • Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study
    • MiR-378a-3p acts as a tumor suppressor in gastric cancer via directly targeting RAB31 and inhibiting the Hedgehog pathway proteins GLI1/2
    Show more Original Article

    Similar Articles

    Keywords

    • Gastric cancer
    • Bioinformatics
    • neoepitope
    • residue substitution
    • immunotherapy

    Navigate

    • Home
    • Current Issue

    More Information

    • About CBM
    • About CACA
    • About TMUCIH
    • Editorial Board
    • Subscription

    For Authors

    • Instructions for authors
    • Journal Policies
    • Submit a Manuscript

    Journal Services

    • Email Alerts
    • Facebook
    • RSS Feeds
    • Twitter

     

    © 2023 Cancer Biology & Medicine

    Powered by HighWire